PRMS Dashboard for Monitoring Performance & Accrual of Underrepresented Populations

D. Bitenas, J. Klingman, H. Rothering, M. Gadepalli, E. Lennstrom

Fred Hutchinson Cancer Center

1. Background

As an NCI-Designated Comprehensive Cancer Center, the Fred Hutchinson Cancer Center operates a two-stage Protocol Review and Monitoring System (PRMS) that ensures rigorous oversight of all cancer clinical trials across three institutions (Fred Hutch, University of Washington, Seattle Children's). The National Cancer Institute (NCI) has reinforced the importance of enhancing diversity, equity, and inclusion in the Cancer Center Support Grant (CCSG) guidelines, including how the PRMS considers and monitors the accrual of underrepresented populations into clinical trials.

2. Goals

The Fred Hutch PRMS has updated its policy for monitoring underperforming trials and is evolving its monitoring process to address the accrual of underrepresented populations into clinical trials. A dashboard is in progress to provide a real-time reporting tool that augments PRMS portfolio reviews and monitoring. The tool also forecasts performance and will provide study teams with an opportunity to preemptively close underperforming trials and prioritize recruitment efforts that address protocol deficiencies.

3. Solutions and Methods

A group from the Fred Hutch PRMS and clinical trials office have created Tableau dashboards that leverage data from OnCore, including the ePRMS console, to display accrual over time, accrual and study duration goals, annual accrual goals defined by the PRMS policy, details of prior second stage monitoring reviews, and accrual demographic data (age, gender, race, and ethnicity). The tool provides two dashboards, a research portfolio overview, and a PRMS monitoring overview for trial-specific performance.

4. Outcomes

The research portfolio overview can be filtered by Research Group and includes a list of open trials available for PRMS monitoring. It provides a performance snapshot with key metrics that highlight trial performance. A heatmap is included to forecast when trials will be monitored by PRMS and indicate performance with red-yellow-green indicators. The Research portfolio overview also displays accrual demographics over time.

The PRMS monitoring overview can be filtered by trial and includes important protocol details. It provides a performance snapshot with key metrics such as study duration, accruals to date, the next PRMS monitoring review date, and forecasted performance outcomes. Trial performance is displayed as both accrual over time (with accrual and study duration targets intersecting a line chart) and accrual at previous monitoring reviews (with accruals and annual targets displayed on a bar chart). Trial accrual demographics are displayed as percentages of total accrual.

5. Lessons Learned and Future Directions

The dashboards will go live in the spring of 2023 and will provide an opportunity to streamline PRMS portfolio and monitoring reviews. Building the dashboards highlighted how some OnCore fields were underutilized and resulted in building new processes to include more data in OnCore that could be

electronically accessed. The performance charts will augment PRMS reviews by displaying the multifaceted attributes that influence performance assessments. The dashboards display accrual and demographic trends that will highlight recruitment efforts needing improvement and enhance collaborations with the Office of Community Outreach and Engagement. In the future, we plan to include additional data sources, like catchment area demographics, to highlight the adequacy of recruitment plans and policies. The dashboards will evolve with stakeholder feedback and in conjunction with institutional priorities in diversity and equity.